- Home
- IMG vs ICU Comparison
IMG vs ICU Comparison
Compare IMG & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMG
- ICU
- Stock Information
- Founded
- IMG 2011
- ICU 2018
- Country
- IMG Hong Kong
- ICU United States
- Employees
- IMG N/A
- ICU N/A
- Industry
- IMG
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- IMG
- ICU Health Care
- Exchange
- IMG NYSE
- ICU Nasdaq
- Market Cap
- IMG 10.3M
- ICU 9.5M
- IPO Year
- IMG 2020
- ICU N/A
- Fundamental
- Price
- IMG $0.26
- ICU $0.77
- Analyst Decision
- IMG
- ICU
- Analyst Count
- IMG 0
- ICU 0
- Target Price
- IMG N/A
- ICU N/A
- AVG Volume (30 Days)
- IMG 1.4M
- ICU 6.3M
- Earning Date
- IMG 08-18-2025
- ICU 08-12-2025
- Dividend Yield
- IMG N/A
- ICU N/A
- EPS Growth
- IMG N/A
- ICU N/A
- EPS
- IMG N/A
- ICU N/A
- Revenue
- IMG $1,930,291.00
- ICU $428,000.00
- Revenue This Year
- IMG $695.32
- ICU $754.07
- Revenue Next Year
- IMG N/A
- ICU $100.09
- P/E Ratio
- IMG N/A
- ICU N/A
- Revenue Growth
- IMG 9.80
- ICU N/A
- 52 Week Low
- IMG $0.23
- ICU $0.31
- 52 Week High
- IMG $8.00
- ICU $9.56
- Technical
- Relative Strength Index (RSI)
- IMG N/A
- ICU 53.19
- Support Level
- IMG N/A
- ICU $0.51
- Resistance Level
- IMG N/A
- ICU $0.82
- Average True Range (ATR)
- IMG 0.00
- ICU 0.12
- MACD
- IMG 0.00
- ICU 0.04
- Stochastic Oscillator
- IMG 0.00
- ICU 65.75
About IMG CIMG INC
CIMG Inc is a coffee and technologies company. The company is a co-packer of single-serve pour-over coffee, coffee brew bags and Dripkits. The company's brand portfolio includes Coffee Blenders, Twin Peaks, Active Cup, Relax Cup, Think Cup, Nude Cup, Pine Ranch Coffee, and Dripkit. Its geographical segments are North America, which accounts for the majority of revenue; and South Korea.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.